THE ANALGESIC EFFECT OF MS CONTIN, SRM RHOTARD FOR SEVERE CANCER PAIN IN 145 PATIENTS

Aim:To evaluate the analgesic effect of MS Contin and SRM-Rhotard for severe cancer pain and improving quality of life for patients. Methods: There were 145 cases histopathologically proven mid and advanced cancer patients (pts) with severe pain. 83 pts were treated with Ms Contin (group A), 62 pts with SRM Rhotard (group B). Their initial dosage in group A and B were 30mg/12hours. According to effect of pain relief, an increament of 30mg /12hours was given to remit pain effectively. Result: The effective rate of MS Contin and SRM Rhoard was 95.2% and 93.5%, respectively. Complete remission rate was 81.9% and 80.6% respectively, duration of pain relief 9.1±4.1h and 8.7±4.4h. The results showed that MS Contine has a similar analgestic effect and duration with SRM Rhotard (P0.05). Life quality was elevated for one grade in 62 and 47 pts after treatment. There were significant difference in life quality after treatment (P0.01). The pain relief in patients with osteocope, visceral pain, soft tissue infiltrative pain were better than neurological pain. There were significant difference between neuralgia and other types of pain (P0.01). The main aversive side effects of MS Contin or SRM Rhotard were constipation, nausea, vomiting, somnolence, retention of urine, et al. Concusion: MS Contin and SRM Rhotard could effectively remit severe cancer pain, with long duration of pain relief, and rather weak side effects resulting in significant improvement of patients quality of life. It could be the first choice in the control of severe cancer pain.